Trial Profile
Multi-center cooperative clinical study on the renoprotective effect of DPP-4 inhibitor (Vildagliptin) in Diabetic nephropathy patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacodynamics; Therapeutic Use
- 30 Mar 2013 New trial record